As the popularity of glucagon-like peptide-1 (GLP-1) receptor agonists—such as semaglutide and tirzepatide—continues to skyrocket for the management of obesity and type 2 diabetes, the medical community is grappling with the downstream effects of these medications on elective surgery. A recent, groundbreaking study published in the April issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS), offers a critical, long-overdue examination of how these drugs influence outcomes in patients undergoing body contouring procedures, specifically panniculectomies.
The findings suggest a complex, dual-natured reality: while these medications do not appear to spike overall surgical risk, they may subtly alter the body’s physiological approach to wound healing.
The Intersection of Weight Loss and Plastic Surgery
Body contouring procedures, such as the abdominal panniculectomy, serve as a vital final step for many patients who have achieved massive weight loss. A panniculectomy specifically targets the removal of the "pannus"—the apron of loose, redundant skin and subcutaneous fat that persists after significant weight reduction.
For years, plastic surgeons have focused on patient optimization—ensuring that a patient’s nutritional and metabolic status is stable before undergoing such extensive tissue resection. However, the rapid integration of GLP-1 receptor agonists (GLP1ra) into standard care has created a new variable. Many plastic surgeons now encounter patients who are actively taking these medications to maintain their weight or manage metabolic comorbidities, leading to urgent questions regarding whether these drugs should be paused, tapered, or continued during the perioperative period.
A Ten-Year Retrospective Analysis: The Study Design
Led by Dr. Zachary Andrew Koenig of the West Virginia University School of Medicine, the research team sought to clarify the clinical impact of GLP1ra use. Recognizing that West Virginia boasts some of the highest prescription rates for these medications in the United States, the team was uniquely positioned to observe a large cohort of affected patients.
The study analyzed 373 patients who underwent non-bariatric abdominal panniculectomy at a single medical center between 2013 and 2023. By excluding patients who were also undergoing concurrent bariatric or hernia repair surgeries, the researchers isolated the specific influence of GLP1ra on skin and soft tissue healing.
Of the total cohort, 21.7% were documented as using GLP-1 medications prior to their procedure. Perhaps the most striking trend noted by the researchers was the "sharp increase" in the use of these medications among the patient population in the final years of the study, mirroring national trends in pharmaceutical consumption.
Chronology of Findings: From Baseline to Post-Op
To understand the full scope of the study, one must look at the comparative baseline of the patients involved. The researchers divided the cohort into GLP-1 users and non-users to identify discrepancies in patient demographics and surgical outcomes.
The Baseline Comparison
When comparing the two groups, those on GLP-1 therapy were found to have a higher prevalence of significant health conditions, including:
- Type 2 diabetes
- Hypertension
- Chronic obstructive pulmonary disease (COPD)
Despite these disparate health backgrounds, the body mass index (BMI) between the two groups was not statistically significant, suggesting that the GLP-1 cohort was, in many cases, successfully managing their weight to reach a surgical baseline comparable to those not on the medication.
The Divergence in Healing
The study’s most significant contribution to clinical practice lies in its observation of wound complications. The researchers identified two distinct, opposing trends that emerged in the GLP-1 user group:
- Increased Risk of Delayed Wound Healing: GLP-1 users experienced a significantly higher rate of delayed wound healing (18.5%) compared to the non-GLP-1 group (7.5%).
- Decreased Rate of Seroma: Conversely, those taking GLP-1 medications exhibited a lower incidence of seroma—the accumulation of fluid beneath the surgical site—at 4.9% compared to 14.0% in the non-user group.
Other traditional markers of surgical morbidity, including infection rates, wound dehiscence (the reopening of a surgical incision), and the need for rehospitalization, showed no statistically significant difference between the groups.
Supporting Data: Understanding the Mechanism
The dual finding—higher rates of delayed healing alongside lower rates of seroma—presents a "complex and nuanced" physiological picture.
Seromas are often related to the extent of tissue dissection and the body’s inflammatory response to the creation of dead space beneath the skin flaps. The researchers hypothesize that the mechanisms by which GLP-1 receptor agonists influence systemic inflammation and metabolic flux may have an inhibitory effect on the fluid dynamics that typically lead to seroma formation.
However, the delay in wound healing suggests that the cellular processes required for collagen synthesis and tissue remodeling—which are vital for closing a large surgical wound—may be subtly suppressed or altered by the presence of these medications. Because these findings remained significant even after adjusting for other confounding variables (such as age, diabetes, and smoking status), the authors conclude that the medication itself is the likely driver of this physiological shift.
Official Responses and Clinical Perspectives
Dr. Koenig and his co-authors emphasize that while the findings provide a "valuable data point" in a rapidly evolving field, they do not necessarily call for a blanket ban on GLP-1 usage prior to surgery. Instead, the study serves as a call for "proactive management."
"Our findings suggest that while GLP1ra therapy does not appear to increase major surgical risk, it may affect specific aspects of healing that warrant proactive management," the authors stated.
The medical community, including the American Society of Plastic Surgeons, is currently in the process of drafting more robust, evidence-based guidelines. Until such formal protocols are established, the consensus among experts—reflected in the tone of the study—is that surgeons must engage in detailed preoperative counseling with patients. Surgeons are encouraged to discuss the potential for slowed recovery and the need for closer monitoring during the first few weeks following a panniculectomy.
Implications for Future Practice
The implications of this study are far-reaching for both patients and practitioners:
1. Personalized Surgical Planning
Plastic surgeons may need to adjust their postoperative recovery protocols. For patients on GLP-1 therapy, more frequent follow-up visits or more conservative activity restrictions may be required to mitigate the risk of delayed healing.
2. The Need for Further Research
As the study authors note, this research represents a 10-year retrospective analysis. While valuable, it highlights the "unique mechanisms" of these drugs that are not yet fully understood. Future prospective, randomized studies are necessary to determine if a "washout period"—pausing the medication for a specific number of weeks before surgery—would eliminate the risk of delayed healing.
3. Educating the Patient
Patients must be informed that GLP-1 drugs, while highly effective for weight management, are not physiologically neutral in the context of major surgery. Providing patients with clear expectations regarding the recovery timeline can reduce anxiety and ensure that minor delays in healing are managed early before they progress to major complications.
4. A New Standard of Care
As the prevalence of GLP-1 usage continues to rise, the plastic surgery field is moving toward a future where metabolic optimization involves not just weight loss, but the careful titration of medications that influence the body’s structural repair processes.
Conclusion
The study published in Plastic and Reconstructive Surgery provides a crucial foundation for understanding the surgical footprint of the GLP-1 era. By demonstrating that these medications neither create catastrophic surgical risk nor are entirely benign, Dr. Koenig and his colleagues have provided surgeons with the evidence needed to refine their clinical approach.
As we move forward, the "nuanced interplay" between these drugs and tissue healing will likely become a standard component of preoperative assessments. For now, the takeaway is clear: while the goal of body contouring remains the same, the path to achieving those results in the age of GLP-1s requires a higher level of vigilance, ongoing research, and a commitment to personalized, evidence-based care.
About the Source:
Plastic and Reconstructive Surgery® is the leading medical journal for the field of plastic surgery, providing an international forum for the latest research and clinical innovations. Published by Wolters Kluwer, the journal remains a cornerstone of the American Society of Plastic Surgeons’ commitment to medical education and patient safety. For further information on the study, "Perioperative GLP-1 Receptor Agonist Use and Surgical Outcomes in Nonbariatric Abdominal Panniculectomy: A 10-Year Retrospective Analysis," readers can visit the journal’s official portal.
About the Author
